Iron supplementation is the first line of treatment of iron deficiency in most women, but we do not know when the best time is to supplement in the context of the menstrual cycle. With this study, we aim to measure and compare iron status, hepcidin, inflammatory markers, hormones estrogen and progesterone and changes in iron absorption at various points throughout the menstrual cycle, with a long-term view to determine best time for iron supplementation in relation to the menstrual cycle.
To date, very few studies have assessed iron absorption in relation to a woman's menstrual cycle. Although oral iron supplementation is considered the first line of treatment for iron deficiency in most women, there is no knowledge on the relationship between this intervention in the context of the menstrual cycle, and more specifically there is no knowledge on its potential implications for the most appropriate timing of iron supplementation. A better understanding of iron absorption during the menstrual cycle as well as kinetics of key parameters could allow the design of adapted and/or new interventions (e.g., timing of iron supplementation in relation to different phases of the menstrual cycle) to mitigate iron deficiency in menstruating women and can inform programs aimed at addressing iron deficiency
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
10
Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
ETH Zurich
Zurich, Switzerland
Fractional iron absorption (%)
Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the labelled test meals.
Time frame: Day 2, 18, 22, 26 and 40
Hemoglobin concentration (g/L)
Haemoglobin will be measured to determine presence of anaemia
Time frame: Screening, day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 40
Serum ferritin (microg/L)
Iron status parameter
Time frame: Screening, day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Serum transferrin receptor (mg/L)
Iron status parameter
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Serum iron (microg/mL)
Iron status parameter
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Serum hepcidin (nmol/L)
Hepcidin, a major regulator of iron absorption and influenced by inflammation, will be measured
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Alpha-1-acid glycoprotein (g/L)
Chronic inflammation parameter
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
C-reactive protein (mg/L)
Acute inflammation parameter
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Serum estradiol (pg/mL)
Hormonal parameter
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Serum progesterone (ng/mL)
Hormonal parameter
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Total iron binding capacity (microg/mL)
Total iron binding capacity will be measured to determine the presence of iron deficiency
Time frame: Day 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28
Menstrual blood volume loss/cycle
Semi-quantitative assessment to measure menstrual blood loss per cycle
Time frame: Menstruation